重组HIV表面抗原gp120的表达纯化及免疫学鉴定

为研制具有流行特点的HIV血清学诊断试剂,采用pET系统表达HIV-1表面糖蛋白gp120。研究发现,全长的gp120在E.coli中不能有效表达;N端半长的gp120可以表达,但表达量很低;仅保留N端1/3的gp120(包含gp120V1/V2抗原决定簇)有效表达,表达蛋白占菌体总蛋白的18%;Westernblot显示较好的反应原性;通过金属螯合层析,产物得到完全纯化。在这些结果的基础上,我们表达了流行株的gp120片段,为探索gp120在大肠杆菌的高效表达,建立针对中国人群的HIV血清学诊断系统奠定基础。     

人类免疫缺陷病毒1型gp140包膜蛋白三聚体在哺乳动物细胞中的高效表达及其性质鉴定

本研究目的是通过优化1型人类免疫缺陷病毒(HIV-1)gp140编码基因的密码子和克隆设计,从而实现在293T哺乳动物细胞中高效表达,并对纯化获得的gp140蛋白进行抗原性质鉴定。在本研究中选择HIV-1B亚型NL4-3全基因序列为模板进行gp140克隆构建,通过密码子优化、信号肽替换、增加柔性linker、三聚体折叠序列等方法优化设计。通过HIV-1转录反式激活因子tat共转HEK293T细胞进行gp140蛋白表达,采用镍柱纯化。SDS-PAGE、Western blot、ELISA、负染电镜等结果显示目的蛋白纯度高于70%,每升培养基可获得0.5mg gp140蛋白,并且具有良好的抗原活性,电镜下呈现三聚体结构。通过弗氏佐剂与目的蛋白混合免疫Balb/c小鼠,检测小鼠免疫血清显示gp140蛋白能有效刺激机体产生免疫应答。本研究通过优化表达获得B亚型HIV-1NL4-3gp140蛋白,为HIV-1病毒包膜蛋白结构和重组疫苗研究奠定基础。     

重组HIV表面抗原gp120的表达纯化及免疫学鉴定

为研制具有流行特点的HIV血清学诊断试剂,采用pET系统表达HIV－1表达糖蛋白gp120。研究发现,全长的gp120在E.coli中不能有效表达;N端半长的gp120可以表达,但表达量很低;仅保留N端1／3的gp120（包含gp120V1／V2抗决定簇）有效表达,表达蛋白占菌体总蛋白的18％;Western blot显示较好的反应原性;通过金属螯合层析,产物得到完全纯化。在这些结果的基础上,我们表达了流行株的gp120片段,为探索gp120在大肠杆菌的高效表达,建立针对中国人群的HIV血清学诊断系统奠定基础。     

HIV-1 C亚型密码子优化gp120基因重组腺病毒载体的构建及表达

目的构建含有HIV-1C亚型gp120基因重组腺病毒载体,并在293细胞中表达gp120蛋白。方法PCR扩增,获得HIV-1C亚型gp120片段,定向克隆人腺病毒转移载体pTrack-CMV,线性化后转化至含有腺病毒骨架载体pAd-easy-1的大肠埃希菌BJ5183,获得重组子prAd—gp120,PacI酶切纯化后转染293细胞,包装成复制缺陷型重组腺病毒vAd—gp120。结果经PCR、酶切及DNA测序,插入片段大小、方向正确,获得了具有感染力的vAd—gp120重组腺病毒;通过Western印迹检测,重组腺病毒在293细胞中表达出分子量为120kD的蛋白。结论成功构建了含有HIV-1C亚型gp120基因重组腺病毒载体,并获得该基因的表达。     

人HCN2真核表达载体的构建及在HEK293细胞中的表达

目的：构建含有人HCN2基因的真核表达载体,并观察在人胚胎肾细胞（HEK293）中的表达情况。方法：对人HCN2基因全序列进行分析,进行oligo设计,通过PCR,扩增HCN2全长cDNA,通过双酶切（XhoI和BamHI）装入真核表达载体pIRES2-EGFP中,脂质体法转染入HEK293细胞中,利用真核表达载体中带有绿色荧光蛋白GFP报告基因,对转染效率进行监测,采用反转录-聚合酶链反应检测HCN2 mRNA表达,全细胞膜片钳技术检测HCN2通道电流。结果：测序及酶切结果表明HCN2基因正确,荧光显微镜下,转染细胞观察到绿色荧光,反转录-聚合酶链反应检测到HCN2 mRNA表达,膜片钳检测到hHCN2基因编码的通道电流。结论：成功地构建了HCN2真核表达载体并进行了起搏通道HCN2基因的异源性表达。     

人HCN2 真核表达载体的构建及在HEK293 细胞中的表达

目的:构建含有人HCN2基因的真核表达载体,并观察在人胚胎肾细胞(HEK293)中的表达情况。方法:对人HCN2基因全序列进行分析,进行oligo设计,通过PCR,扩增HCN2全长cDNA,通过双酶切(XhoI和BamHI)装入真核表达载体pIRES2-EGFP中,脂质体法转染入HEK293细胞中,利用真核表达载体中带有绿色荧光蛋白GFP报告基因,对转染效率进行监测,采用反转录-聚合酶链反应检测HCN2 mRNA表达,全细胞膜片钳技术检测HCN2通道电流。结果:测序及酶切结果表明HCN2基因正确,荧光显微镜下,转染细胞观察到绿色荧光,反转录-聚合酶链反应检测到HCN2 mRNA表达,膜片钳检测到hHCN2基因编码的通道电流。结论:成功地构建了HCN2真核表达载体并进行了起搏通道HCN2基因的异源性表达。     

单纯疱疹病毒2型感染细胞多肽27真核表达质粒的构建及表达

为了构建单纯疱疹病毒2型(HSV-2)感染细胞多肽27(ICP27)真核表达质粒,应用PCR技术从HSV-2 333株的基因组中扩增ICP27基因,并连接至真核表达载体pEGFPC2,对阳性克隆进行菌落PCR、酶切和测序鉴定后,成功构建了重组质粒pEGFPC2-ICP27。用X fect转染试剂盒将重组质粒pEGFPC2-ICP27转染至Vero细胞中,并用RT-PCR及W estern b lot-ting检测其表达情况。结果显示,ICP27基因在Vero细胞中得到正确表达。真核表达质粒pEGFPC2-ICP27的构建成功,为进一步研究ICP27对宿主细胞的影响奠定了基础。     

EEF1A2基因慢病毒表达载体的构建及慢病毒表达系统的建立

利用PCR方法合成EEF1A2的基因全长,经NotⅠ和NsiⅠ酶切后克隆到慢病毒载体pGLV5-EF1a-EGFP/Puro上。构建的重组质粒pGLV5/EEF1A2经PCR、酶切及测序鉴定正确后,利用慢病毒表达系统(pGLV5 Lentiviral Expression Systems),将重组质粒与包装系统质粒(pVSV-G,pGag/Pol,pRev)4质粒共转染293T细胞,收集培养上清并感染人胰腺癌SW1990细胞,经嘌呤霉素筛选出稳定过表达细胞株EEF1A2/SW1990。Real-time PCR和West-ern blot检测结果显示EEF1A2在EEF1A2/SW1990细胞中表达较原代细胞明显增高(P<0.05),MTT结果显示EEF1A2/SW1990细胞的增殖能力亦较原代细胞显著增强(P<0.05)。成功构建了EEF1A2基因的慢病毒载体质粒pGLV5-EEF1A2及其慢病毒表达系统,并筛选出稳定过表达EEF1A2的人胰腺癌细胞株EEF1A2/SW1990。     

MicroRNA122真核表达载体的构建及在HepG2细胞中的表达与检测

为进一步研究microRNA的功能及作用靶标提供技术平台,构建microRNA真核表达载体。从HepG2215细胞基因组DNA扩增microRNA122前体,克隆到pEGFP-C1的载体上,经测序鉴定后转染至HepG2细胞中,荧光显微镜观察绿色荧光蛋白表达情况并提取基因组总RNA,RT-PCR检测microRNA122表达,TA克隆鉴定。结果表明,成功构建microRNA122真核表达载体,并证实其在真核细胞HepG2中表达。此方法成功构建microRNA表达,并为后续研究提供良好的技术平台。     

pIRES2-EGFP-IL-1ra-Fcε真核表达载体的构建及鉴定

采用RT-PCR方法从哮喘大鼠脾细胞中克隆IgE恒定区cDNA,同时从载体pBV220-IL-1ra中克隆IL-1ra基因.利用重叠延伸PCR技术构建IL-1ra-Fcε融合基因.将其克隆入真核表达载体pIRES2-EGFP,以脂质体法转染293T细胞,同时采用气管滴注方式滴注大鼠肺部.经Westernblot、RT-PCR及荧光显微镜观察此融合基因在293T细胞及大鼠肺组织中实现了表达,为过敏性哮喘基因治疗奠定了基础.     

Ficolin-2 binds to HIV-1 gp120 and blocks viral infection

Ficolin-2 is a lectin complement pathway activator present in normal human plasma and usually associated with infectious diseases, but little is known about the role of ficolin-2 in human immunodeficiency virus (HIV) infection. Here, we describe our novel findings that serum ficolin-2 concentrations of 103 HIV-1 patients were much higher compared to those of 57 healthy donors. In vitro analysis showed that HIV-1 infection could enhance ficolin-2 expression. We further demonstrated that recombinant ficolin-2 protein could bind with HIV-1 envelope glycoprotein gp120, and subsequently induce complement dependent cytotoxicity. Moreover, ficolin-2 could block the entry of HIV-1 into target cells (TZM-b1 and MT-2 cells) and infection in a ficolin-2 dosedependent manner. To our knowledge, this is the first report about the protective role of ficolin-2 against HIV-1 infection and our study suggests that ficolin-2 is an important human innate immune molecule against HIV.

Open image in new window

     

表达人去唾液酸糖蛋白受体分子细胞系的建立

目的构建稳定表达人肝细胞表面分子去唾液酸糖蛋白受体（asialoglycoprotein receptor,ASGPR）的细胞系。方法逆转录PCR扩增人肝组织ASGPR大亚基H1全编码序列,插入到真核表达载体plRES2EGFP中,重组质粒pIRES2EGFP／ASGPRH1转染HeLa细胞,G418筛选,RT—PCR,Western印迹及免疫荧光检测ASGPRH1的表达。结果成功构建了pIRES2EGFP／ASGPRH1重组质粒,该质粒转染HeLa细胞后,Western印迹及免疫荧光均检测到ASGPRHI蛋白的表达。结论成功建立了稳定表达人ASGPRH1的细胞系,为进一步研究ASGPR分子奠定了基础。     

p100蛋白表达抑制的HepG2肝癌细胞稳定株的建立

目的建立p100表达抑制的HepG2肝癌细胞稳定株,并初步探讨p100在HepG2肝癌细胞中的功能。方法用脂质体将含有真核细胞筛选标记Neo和GFP的p100 shRNA表达质粒转染入HepG2细胞。经G418耐药筛选稳定整合抗药基因的细胞单克隆;荧光镜检GFP阳性细胞单克隆,挑取单克隆;Western检测HepG2细胞稳定株HepG2（p100I）中p100表达的抑制效果;平板细胞克隆形成实验检测细胞克隆形成能力;MTS法检测细胞存活;划痕实验检测细胞迁移能力。结果成功获得了p100表达抑制的HepG2肝癌细胞稳定株HepG2（p100I）,其中p100的表达明显降低。并且实验表明,该p100表达抑制稳定株的克隆形成能力,抵抗化疗药物Cisplatin诱导的细胞死亡的能力和迁移能力明显低于对照组细胞。结论p100表达抑制的HepG2肝癌细胞稳定株的建立为研究p100蛋白在肝癌中的作用提供了体外细胞系模型,基于此稳定株的研究,发现p100能够影响HepG2肝癌细胞的多种细胞功能。     

HIV-1 gp120对鼠海马长时程增强效应的影响

为了探讨人类免疫缺陷病毒Ⅰ型(HIV-1)的包膜糖蛋白gp120对鼠海马脑片CA1区的突触传递及可塑性的影响,应用离体脑片记录技术,记录大鼠海马CA1区的兴奋性突触后电位(excitatory postsynaptic potential,EPSP),研究了gp120对高频电刺激Schaffer侧支引起的鼠长时程增强效应(long-term potentiation,LTP)的影响.结果发现:gp120对大鼠海马CA1区LTP产生抑制作用,对其基础EPSP没有影响,而且这种抑制效应随着gp120浓度增大而增强,即具有剂量依赖性.PKA/PKC蛋白激酶抑制剂H7可以反转这种抑制效应.提示:gp120可能是通过抑制海马CA1区的LTP而参与艾滋病相关性痴呆(HIV-1 associated dementia,HAD)的形成.     

Role of Curdlan Sulfate in the Binding of HIV-1 gp120 to CD4 Molecules and the Production of gp120-Mediated TNF-α

To clarify the mechanism by which curdlan sulfate (CRDS) inhibits human immunodeficiency virus (HIV)-1 infection, we examined its influence on the binding of gp120 to CD4 molecules on T cells and macrophages, as well as on the production of TNF-α by gp120-stimulated macrophages (which promotes HIV-1 replication). CRDS treatment of cells not only inhibited the binding of HIV-1 gp120 to CD4⁺ cells, but also inhibited TNF-α production induced by gp120. Inhibition of HIV-1 infection by CRDS may be related to these two actions.     

Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 disease

The pharmacokinetics of mouse V/human C (1,) chimeric monoclonal antibody CGP47 439 specific for the principal neutralizing determinant of human immunodeficiency virus type 1 (HIV-1) was studied in patients with stage IV HIV-1 disease in an open-labeled phase I/IIA trial. Twelve male patients were enrolled and nine completed the study. Patients were divided into three groups according to the extent of CGP 47 439 to bind to gp120 from their viral isolates: undetectable for group 1, modestly reactive for group 2, and strongly reactive for group 3. A first dose of 1, 10, or 25 mg was administered by intravenous infusion to group 1, group 2 and group 3 patients, respectively. The patients then received seven doses of 50, 100, or 200 mg, respectively, every three weeks. CGP 47 439 serum concentrations were determined by an ELISA using monoclonal antibody AB19-4 specific for the idiotope of CGP 47 439. Half an hour after infusion only 25.5–36.1% of the administered antibody was found in the serum, reflecting its rapid distribution in the extravascular space and possibly binding to gp120 antigen in some of the patients. The terminal elimination half-life (T_1/2) was 16.2 days in group 1 patients, 9.7 days in group 2 and in group 3 patients 7.5 days and 9.1 days. An antibody response to CGP 47 439 was not a factor in determining elimination rates, because only very low and transient responses were found in three patients. These results suggest that the reactivity of CGP 47 439 with HIV-1 gp120 contributed to its elimination in HIV-1 infected patients.Abbreviations AIDS aquired immune deficiency syndrome - ARC AIDS-related complex - HIV-1 human immune deficiency virus type 1 - gp120 envelope glycoprotein with 120 KD molecular weight - V3 variable domain of gp120 - PND principle neutralizing determinant of gp120 - IgG immunoglobulin G - CD4⁺ lymphocytes: lymphocytes expressing the CD4 marker V_H and V_L variable heavy and variable light chain region of an antibody - C₁ and C_K constant heavy chain region of gamma l and constant K light chain region of an antibody - anti-id anti-idiotypic - AUC area under curve - T_1/2 terminal elimination half-life - ELISA enzyme-linked imuno sorbent assay - PBS phosphate buffered saline - NP-40 detergent - CDC center of disease control - GMP good manufacturing practice     

The V1/V2 loop of HIV-1 gp120 is necessary for Tat binding and consequent modulation of virus entry

Preventing cell entry of human immunodeficiency virus 1 (HIV-1) is of interest for the development of innovative therapies. We previously reported a specific interaction between HIV-1 envelope glycoprotein 120 (gp120) and Tat at the cell surface, which enhances virus attachment and entry. We also identified a gp120-mimicking peptide, CT319, that competes with gp120 for Tat binding, thus inhibiting HIV-1 infection. Here we report a molecular dissection of gp120 regions involved in this mechanism. Our findings identify the V1/V2 loop of gp120 as involved in Tat binding, and define this interaction as functionally relevant for HIV-1 entry into host cells.